Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 -0.76%25 PB Ratio is 9.07 as of Jul. 26, 2026, which is 36% below its 10-year median of 14.20. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,231 Biotechnology companies, DuoGenic StemCells ranks worse than 85.22% on this metric.
DuoGenic StemCells Corp stock PB Ratio (=9.07) is close to 5-year low of 8.75.
The historical rank and industry rank for DuoGenic StemCells's PB Ratio or its related term are showing as below:
ROCO:7607'
s PB Ratio Range Over the Past 10 Years
Min: 8.75 Med: 14.2 Max: 42.11
Current: 9.07
During the past 5 years, DuoGenic StemCells's highest PB Ratio was 42.11. The lowest was 8.75. And the median was 14.20.
ROCO:7607's PB Ratio is ranked worse than 85.22% of 1231
companies
in the Biotechnology industry
Industry Median: 2.77
vs ROCO:7607: 9.07
During the past 12 months, DuoGenic StemCells's average Book Value Per Share Growth Rate was 160.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of DuoGenic StemCells was -15.90% per year. The lowest was -37.70% per year. And the median was -26.80% per year.
Back to Basics: PB Ratio
DuoGenic StemCells (ROCO:7607) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
DuoGenic StemCells PB Ratio Related Terms
DuoGenic StemCells PB Ratio Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, DuoGenic StemCells's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's PB Ratio distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
DuoGenic StemCells (ROCO:7607) has a PB Ratio of 9.07 as of Jul. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DuoGenic StemCells and its competitors. This is 36% below median its historical median of 14.20. Over the past decade, DuoGenic StemCells' PB Ratio has ranged from 8.75 to 42.11. According to the industry distribution chart, DuoGenic StemCells ranks #1049 out of 1231 companies in the Biotechnology industry, placing it in the top 85.2%.
Is DuoGenic StemCells' PB Ratio too high?
DuoGenic StemCells' current PB Ratio of 9.07 is 36% below median its 10-year median of 14.20. Over the past 10 years, this metric has ranged from a low of 8.75 to a high of 42.11. The Biotechnology industry median PB Ratio is 2.77. DuoGenic StemCells' value of 9.07 is 227.4% above this industry median. Based on the distribution chart, DuoGenic StemCells ranks #1049 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #1049 out of 1231 companies for PB Ratio. This places DuoGenic StemCells in the lower half of its industry. The industry median PB Ratio is 2.77. DuoGenic StemCells' value of 9.07 is 227.4% above this benchmark. Historically, DuoGenic StemCells' own PB Ratio has ranged from 8.75 to 42.11 over the past decade. While the company's 10-year median is 14.20 vs. the industry median of 2.77, DuoGenic StemCells has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.77, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current PB Ratio of 9.07 is 227.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median PB Ratio is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current PB Ratio is 9.07, which is 36% below median its own 10-year median of 14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current PB Ratio is 9.07, which is 36% below median its 10-year median of 14.20 and 227.4% above the Biotechnology industry median of 2.77. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current PB Ratio is 9.07 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
PB Ratio: 9.07 (36% below median its 10-year median of 14.20)
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
Industry Position: 227.4% above the Biotechnology median (#1049 of 1231)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
